Patents by Inventor Paul Spellman

Paul Spellman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY
    Publication number: 20120077694
    Abstract: Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 29, 2012
    Applicant: The Regents of the University of California
    Inventors: Joe W. Gray, Jane Fridlyand, Richard Neve, Paul Spellman, Koei Chin, Zhi Hu, Frederic Waldman
  • TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY
    Publication number: 20090203051
    Abstract: Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
    Type: Application
    Filed: December 8, 2008
    Publication date: August 13, 2009
    Applicant: The Regents of the University of California
    Inventors: Joe W. Gray, Jane Fridlyand, Richard Neve, Paul Spellman, Koei Chin, Zhi Hu, Frederic Waldman
  • SYSTEMS AND METHODS FOR PREDICTING RESPONSE OF BIOLOGICAL SAMPLES
    Publication number: 20090177450
    Abstract: Embodiments relate to genomic technologies using adaptive spline analysis that predict responses of cancer cells. For example, responses of cancer cells to specific medications and/or treatments may be predicted based on adaptive linear spline analyses.
    Type: Application
    Filed: December 11, 2008
    Publication date: July 9, 2009
    Applicant: Lawrence Berkeley National Laboratory
    Inventors: Joe W. Gray, Debopriya Das, Nicholas Wang, Wen-Lin Kuo, Paul Spellman